LL-37: adverse events and evidence limits
A synthetic LL-37 trial involved 34 venous-leg-ulcer patients receiving topical treatment or placebo for four weeks. The abstract reports no identified local or systemic safety concern. [1]
The abstract lacks event lists and counts; this does not mean zero events. Topical findings do not establish injectable or systemic-use safety. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Local or systemic safety concerns | 34 venous-leg-ulcer patients, topical LL-37 or placebo for four weeks | The abstract reports no identified safety concern; it gives no event list or counts — this does not mean zero events; topical findings do not establish injectable or systemic-use safety | [1] |
References
- Alvar Grönberg et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial https://doi.org/10.1111/wrr.12211.